VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

vP869
Vaccine Information
  • Product Name: Yellow Fever vaccine using vaccinia virus expressing YFV prM and E proteins
  • Vaccine Ontology ID: VO_0004152
  • Type: Recombinant vector vaccine
  • Status: Research
  • E gene engineering:
    • Type: Recombinant vector construction
    • Description: The vaccinia virus was uses as recombinant vector (Pincus et al., 1992).
    • Detailed Gene Information: Click Here.
  • Vector: Vaccinia virus
  • Immunization Route: Intraperitoneal injection (i.p.)
Host Response

Mouse Response

  • Host Strain: Outbred Swiss Mice
  • Vaccination Protocol: Groups of 20 3-week-old outbred Swiss mice were immunized by intraperitoneal (i.p.) injection with 107 PFU of vaccinia virus (VP869) or 106 PFU of YFV-17D, and 3 weeks later sera were collected from selected mice (Pincus et al., 1992).
  • Challenge Protocol: One half of the mice in each group were then either reinoculated with the recombinant virus (VP869) or YFV-17D, or challenged by intracranial (i.c.) injection with a 1: 105 dilution of brain homogenate prepared from suckling mice infected with the French neurotropic YFV (approximately 100 LD50). Three weeks later, the boosted animals were bled and then challenged with the French neurotropic strain of YFV. Following challenge, mice were observed daily for 3 weeks(Pincus et al., 1992).
  • Efficacy: Mice immunized once or twice with VP869 or YFV-17D were protected from French neurotropic virus challenge. Levels of protection achieved by immunization with VP869 were equivalent to those achieved by immunization with YFV-17D (Pincus et al., 1992).
References
Pincus et al., 1992: Pincus S, Mason PW, Konishi E, Fonseca BA, Shope RE, Rice CM, Paoletti E. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology. 1992; 187(1); 290-297. [PubMed: 1736531].